Search
for
Sort by
Research 26
- Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
- A Case of Cicatricial Alopecia Associated with Erlotinib
- Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer
- Scalp Pustule as a Manifestation of Erlotinib-Induced Skin Toxicity: Report of Two Cases and Literature Review
- Abstract 4350: Pharmacodynamic biomarkers: Evaluation of oncology drug target engagement in human plucked scalp and beard hair
- Are all adverse effects undesirable? a case of chemotherapy induced adverse effect- an exception!?
- Effets secondaires cutanéo-muqueux des nouvelles molécules anticancéreuses: Inhibiteurs de l'EGF-R, inhibiteurs de tyrosine kinase et stabilisateurs du fuseau mitotique
- DIETARY AND PHARMACO-THERAPY IN SKIN DISEASES
- Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- The pharmacovigilance analysis of adverse events of erlotinib based on the open access FAERS database
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Cetuximab-Associated Elongation of the Eyelashes
- Management of Cutaneous and Extracutaneous Side Effects of Smoothened Inhibitor Therapy for Advanced Basal Cell Carcinoma
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Management of Toxicities of Targeted Therapies
- Topical Application of Aprepitant Inhibits Erlotinib-induced Facial Dermatitis/Hair Loss
- Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib
- Cutaneous side-effects of EGFR inhibitors and their management.
- The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
- The Cutaneous Epidermal Growth Factor Network: Can it be Translated Clinically to Stimulate Hair Growth?
- Persistent hair growth during treatment with the EGFR inhibitor erlotinib
- Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
- Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor
- Advancements and Applications of Injectable Hydrogel Composites in Biomedical Research and Therapy
- The Cutaneous Epidermal Growth Factor Network: Can it be Translated Clinically to Stimulate Hair Growth? - eScholarship